Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD9ISG)

Drug Name
SM-88 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 2/3 [1]
Prostate cancer 2C82.0 Phase 2 [2]
Cross-matching ID
PubChem CID
3125
CAS Number
CAS 658-48-0
TTD Drug ID
DMD9ISG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Free radical (FRD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Disufenton sodium DMJS8V3 Ischemia 8B10-8B11 Phase 3 [3]
RRx-001 DMQM2FH Small-cell lung cancer 2C25.Y Phase 3 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Free radical (FRD) TT8E7Z0 NOUNIPROTAC Stimulator [2]

References

1 ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8.
4 Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8.